The patent application concerns the proprietary set of primers, the diagnostic method and the reaction mixture composition for genetic diagnosis of MRSA (methicillin-resistant staphylococcus aureus) in the LAMP technique. The assay is part of the systemic infections diagnostic panel planned for Genomtec ID – a mobile genetic testing platform dedicated for doctor’s office, ambulance, airport or pharmacy. In addition to methicillin-resistant staphylococcus aureus, the systemic infections panel also includes Lyme disease and meningitis.
Methicillin-resistant staphylococcal strains are a common cause of hospital-acquired infections and constitute a significant problem due to difficulties in treatment and rapid onset of disease and its progression. The type of resistance developed by microorganisms means that you lack susceptibility to all beta-lactam antibiotics – including penicillins, cephalosporins, monobactams and carbapenems.
– Infections caused by the MRSA strain are characterized by a higher death rate, as well as a longer patient’s hospitalization time, and thus a higher cost of treatment. Therefore, the diagnosis of the MRSA strain, mainly to limit its spread, is an extremely important issue in medicine. The LAMP technology already enables fast and precise diagnostics, and Genomtec ID will accelerate it even more – said Miron Tokarski, co-founder and president of Genomtec.
According to market data, only in the USA, the costs of hospitalization of patients infected with MRSA amounts to about USD 10 billion per year, which means an average of about 60,000 USD per patient[1]. The early detection of MRSA and the isolation of infected patients would allow faster treatment delivery and a significant reduction in hospitalisation costs.
In mid-March this year Genomtec has filed a patent application in Poland for the proprietary set of primers, the diagnostic method and the reaction mixture composition for genetic diagnosis of the bacterial sexually transmitted infections utilizing the LAMP method, which is included in the sexually transmitted diseases panel.
Genomtec already holds two patents and has filed 20 patent applications. The company holds, among others, a patent for a method and a diagnostic system using the contactless heating technique granted in the USA and Poland. At the same time, the company is waiting for the decision of the European Patent Office and local patent offices of China, Hong Kong, Japan, Brazil and Canada. In addition, Genomtec has filed patent applications concerning the contactless heating technique processed by the European Patent Office (EPO), the United States Patent and Trademark Office (USPTO), local offices in China and Japan. Additionally, yet another six assay mixtures covered by patent applications are being processed via the PCT path.
